Last reviewed · How we verify
PA21
PA21 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.
PA21 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | PA21 |
|---|---|
| Also known as | sucroferric oxyhydroxide, Velphoro® |
| Sponsor | Kissei Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (Sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
PA21 works by inhibiting SGLT2, a transporter protein in the kidney's proximal tubule that normally reabsorbs filtered glucose back into the bloodstream. By blocking this reabsorption, the drug increases urinary glucose excretion, thereby lowering blood glucose levels independent of insulin secretion. This mechanism also provides cardiovascular and renal protective benefits beyond glycemic control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
Key clinical trials
- PA21 Safety and Efficacy in Adult Chinese Subjects (PHASE3)
- Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)
- A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia (PHASE3)
- The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum (PHASE2)
- A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia (PHASE3)
- A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia (PHASE3)
- A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia (PHASE3)
- PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PA21 CI brief — competitive landscape report
- PA21 updates RSS · CI watch RSS
- Kissei Pharmaceutical Co., Ltd. portfolio CI